Predictive Technology Group, Inc. Announces Board Appointments
March 19, 2019 at 09:00 am EDT
Share
Predictive Technology Group, Inc. announced the appointment of Senator Orrin G. Hatch and Ronald Barhorst to the company’s Board of Directors, effective immediately. Senator Hatch brings experience from his seven terms as a U.S. Senator including serving as a member and/or chair of various U.S. Senate committees. Mr. Barhorst brings 25 years of experience as a senior executive in the financial services industry and has served as an advisor to the company or its predecessors for nearly 10 years. These two appointments expand Predictive’s Board to six including four independent directors. Senator Hatch served as either the chair or ranking minority member of the Senate Judiciary Committee from 1993 to 2005. He previously chaired the Senate Committee on Health, Education, Labor, and Pensions from 1981 to 1987. Senator Hatch also served as Chairman of the Senate Finance Committee. Mr. Barhorst is chair of The California State University Foundation. He is retired as president and chief executive officer of ING Financial Advisers, LLC and ING Investment Advisors, LLC and Systematized Benefits Administrators, Inc. He was also head of national accounts, healthcare and government markets.
Predictive Technology Group, Inc. is a life science company. The Company, through its subsidiaries, is focused on specific points of the care continuum, including detection, prevention and treatment. Predictive Analytics, Predictive Laboratories, and Predictive Biotech each bring critical solutions to personalized patient care by leveraging its research, genomics, genetic library and expertise in developing bioscience solutions. Predictive Analytics is the repository for its genetic library. Predictive Biotech provides regenerative medicine. Its products are derived from tissue sources rich in properties that support the bodyâs natural ability to heal itself. All products are safely, ethically and minimally processed to deliver allografts that preserve the naturally occurring characteristics and factors of the donor tissue. Its research and use of processing methods has propelled its placental-derived and Whartonâs Jelly umbilical cord-derived products to new heights.